For the record, I didn't I mean to imply they don't have the resources. I believe the FDA didn't want Anavex to take on the risk of running two similar trials. I believe the FDA recommended one and thus the late chance and EU route for PD. Do Rett in the US since we have OD status.
Can anyone logically answer why Missling would state PD to start in 2017 and not even be close to submitting IND to the EMA? I refuse to believe he purposely lied because of the LPC. There has to be another reason.
If PD had a chance to start in 2017, the EMA submission had to occur months ago. It had to have been submitted as early as August. We now know Missling is planning the EMA submission in Q!. Lets see how long that takes. When it does occur, we then can back date the time and see when it would have had to be submitted to have a 2017 start. At that time, we will have proof that either Missling misled us or something else caused the the delay and the move to the EU.
Look at the share price and tell me everything is hunky dory.
Smart money knows. The rest of us are looking for all means possible to justify how overstretched we are investing in this stock.